IP Verse

Chemically Modified Guide Rnas For Crispr/Cas-Mediated Gene Regulation - EP3280803

The patent EP3280803 was granted to Agilent on May 26, 2021. The application was originally filed on Apr 5, 2016 under application number EP16720220A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3280803

AGILENT
Application Number
EP16720220A
Filing Date
Apr 5, 2016
Status
Granted And Under Opposition
Apr 23, 2021
Publication Date
May 26, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDFeb 28, 2022MAIWALDADMISSIBLE
JAMES POOLEAug 9, 2021CARPMAELS & RANSFORDADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJul 28, 2021WICHMANNADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2014068797
DESCRIPTIONUS2014186919
DESCRIPTIONUS2014273226
DESCRIPTIONUS2014302563
DESCRIPTIONUS2014356959
DESCRIPTIONUS4373071
DESCRIPTIONUS4458066
DESCRIPTIONUS4500707
DESCRIPTIONUS4668777
DESCRIPTIONUS4973679
DESCRIPTIONUS5047524
DESCRIPTIONUS5132418
DESCRIPTIONUS5153319
DESCRIPTIONUS5262530
DESCRIPTIONUS5700642
DESCRIPTIONUS7682828
DESCRIPTIONUS8058065
DESCRIPTIONUS8530238
DESCRIPTIONUS8697359
DESCRIPTIONUS8791248
DESCRIPTIONUS8865406
DESCRIPTIONUS8871504
DESCRIPTIONUS8889418
DESCRIPTIONUS8895308
DESCRIPTIONUS8900871
DESCRIPTIONWO2013176772
INTERNATIONAL-SEARCH-REPORTWO2014093635
INTERNATIONAL-SEARCH-REPORTWO2014093712
INTERNATIONAL-SEARCH-REPORTWO2015026885
INTERNATIONAL-SEARCH-REPORTWO2015138510
INTERNATIONAL-SEARCH-REPORTWO2015191693
INTERNATIONAL-SEARCH-REPORTWO2016100951
OPPOSITIONWO2014093712
OPPOSITIONWO2015026885
OPPOSITIONWO2016089433
OPPOSITIONWO2016164356

Non-Patent Literature (NPL) Citations (46) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Addgene PX330-U6-Chimeric_BB-CBh-hSpCas9 (plasmid #42230)", wayback machine, (20150314), page 1, XP055903561
OPPOSITION- Anonymous, "Nucleofector 2b manual", Lonza, (20150000), pages 1 - 20, XP055903576
OPPOSITION- BARRANGOU et al., "Survey and Summary : Advances in CRISPR-Cas9 genome engineering:lessons learned from RNA interference", Expert Opinion on Biological Therapy, (20150000), vol. 15, no. 3, pages 311 - 314, XP055903511
OPPOSITION- DELEAVEY GF et al., "Designing chemically modified common general oligonucleotides for targeted gene silencing", Chem Biol., (20120000), vol. 19, no. 8, pages 937 - 54, XP055905926
OPPOSITION- LATORRE A et al., "Modified RNAs in common general CRISPR/Cas9: An Old Trick Works Again", Angew Chem Int Ed knowledge, (20160216), vol. 55, no. 11, pages 3548 - 3550, XP055905916
OPPOSITION- LI B et al., "Engineering CRISPR-Cpfl crRNAs and mRNAs to maximize genome editing efficiency", Nat Biomed Eng., (20170510), vol. 1, no. 5, pages 1 - 21, XP055905962
OPPOSITION- LI Z et al., "Therapeutic targeting of microRNAs: current common general status and future challenges", Nat Rev Drug Discov, (20140711), vol. 13, no. 8, pages 622 - 38, XP055905929
OPPOSITION- RAHDAR M et al., "Synthetic CRISPR RNA-Cas9-guided an effective date of genome editing in human cells", Proc Natl Acad Sci USA., USA., (20150504), pages E7110 - E7117, XP055905957
OPPOSITION- SHARMA, V.K. et al., "Antisense common general oligonucleotides: Modifications and clinical trials", Medchemcomm, (20140000), vol. 5, pages 1454 - 1471, XP055905942
OPPOSITION- SOUTSCHEK, J. et al., "Therapeutic silencing of an endogenous citable under 54(2) EPC gene by systemic administration of modified siRNAs", Nature, (20040000), vol. 432, pages 173 - 178, XP055905934
OPPOSITION- Yogesh S. Sanghvi, "A Status Update of Modified Oligonucleotides for Chemotherapeutics Applications", Current Protocols in Nucleic Acid Chemistry, Hoboken, NJ, USA , John Wiley & Sons, Inc. , doi:10.1002/0471142700.nc0401s46, ISBN 9780471142706, XP055204827
OPPOSITION- Alfonso Latorre; Ana Latorre; Álvaro Somoza, "Modified RNAs in CRISPR/Cas9: An Old Trick Works Again", Angew. Chem. Int. Ed., (20160000), vol. 55, no. 11, pages 3548 - 3550, XP055602216
OPPOSITION- Dongbo Yu; Hannah Pendergraff; Jing Liu; Holly B Kordasiewicz; Don w Cleveland; Eric e Swayze; Walt f Lima; Stanley t Crooke; Thazha p Prakash; David r Corey, "Single-stranded RNAs use RNAi to potently and allele- selectively inhibit mutant huntingtin expression", Cell, (20120800), vol. 150, pages 895 - 908, XP055166558
OPPOSITION- HSU et al., "Development and Applications of CRISPR-Cas9 for Genome Engineering", Cell, (20140000), vol. 157, no. 6, pages 1262 - 1278, XP055529223
OPPOSITION- John c. Burnett, John j. Rossi, "RNA-Based Therapeutics: Current Progress and Future Prospects", Chemistry & Biology, (20120101), vol. 19, no. 1, doi:10.1016/j.chembiol.2011.12.008, ISSN 10745521, pages 60 - 71, XP055087578
OPPOSITION- Glen f Deleavey; Masad j Damha, "Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing", Chemistry & Biology, (20120000), vol. 9, no. 8, pages 937 - 954, XP055107150
OPPOSITION- Glen f. Deleavey, Masad j. Damha, "Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing", Chemistry & Biology, (20120801), vol. 19, no. 8, doi:10.1016/j.chembiol.2012.07.011, ISSN 10745521, pages 937 - 954, XP055107150
OPPOSITION- K A Lennox, M A Behlke, "Chemical modification and design of anti-miRNA oligonucleotides", Gene Therapy, Macmillan Press Ltd., (20111214), vol. 18, no. 12, doi:10.1038/gt.2011.100, ISSN 09697128, pages 1111 - 1120, XP055156922
OPPOSITION- Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher, "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs", Nature, (20040000), vol. 432, pages 173 - 178, XP002333747
OPPOSITION- Prashant Mali; John Aach; Benjamin Stranges P; Kevin M Esvelt; Mark Moosburner; Sriram Kosuri; Luhan Yang; George M Church, "CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering", Nature Biotechnology, (20130000), vol. 31, pages 833 - 838, XP055149275
OPPOSITION- Jeffry D Sander; Keith Joung J, "CRISPR-Cas systems for editing, Common general regulating and targeting genomes", Nat Biotechnol., (20140000), vol. 32, no. 4, pages 347 - 355, XP055172520
OPPOSITION- Ayal Hendel; Bak Rasmus O; Clark Joseph T; Kennedy Andrew B; Ryan Daniel E; Roy Subhadeep; Steinfeld Israel; Lunstad Benjamin D; Kaiser Robert J; Wilkens Alec B; Bacchetta Rosa; Tsalenko Anya; Dellinger Douglas; Bruhn Laurakay; Porteus Matthew H, "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells", Nature Biotechnology, (20150000), vol. 33, pages 985 - 989, XP055548372
OPPOSITION- Ayal Hendel, Rasmus O Bak, Joseph T Clark, Andrew B Kennedy, Daniel E Ryan, Subhadeep Roy, Israel Steinfeld, Benjamin D Lunstad, Robert J Kaiser, Alec B Wilkens, Rosa Bacchetta, Anya Tsalenko, Douglas Dellinger, Laurakay Bruhn, Matthew H Porteus, "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells", Nature Biotechnology, Nature Publishing Group US, New York, New York, vol. 33, no. 9, doi:10.1038/nbt.3290, ISSN 1087-0156, pages 985 - 989, XP055233915
OPPOSITION- HENDEL A et al., "Chemically 05.04.2016 modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells", Nat Biotechnol., vol. 33, no. 9, doi:10.1038/nbt.3290, (20150629), pages 985 - 989, XP055548372
OPPOSITION- David R Corey, "RNA learns from antisense", Nature Chemical Biology, Nature Pub. Group, (20070101), vol. 3, no. 1, doi:10.1038/nchembio0107-8, ISSN 15524450, pages 8 - 11, XP055007854
OPPOSITION- Prashant Mali; Kevin M Esvelt & George M Church, "Cas9 as a versatile tool for engineering biology", Nature Methods, (20130000), vol. 10, no. 10, pages 957 - 963, XP002718606
OPPOSITION- Ann Ran F; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott & Feng Zhang, "Genome engineering using the CRISPR-Cas9 system", Nature Protocols, (20130000), vol. 8, no. 11, pages 2281 - 2308, XP002744123
OPPOSITION- THRELFALL RN et al., "Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2'-O-methyl oligoribonucleotides", Org Biomol Chem., (20111129), vol. 10, no. 4, doi:10.1039/C1OB06614E, pages 746 - 54, XP055685123
OPPOSITION- KURRECK J, "ANTISENSE TECHNOLOGIES IMPROVEMENT THROUGH NOVEL CHEMICAL MODIFICATIONS", European Journal of Biochemistry, Published by Springer-Verlag on behalf of the Federation of European Biochemical Societies, (20030401), vol. 270, no. 08, doi:10.1046/j.1432-1033.2003.03555.x, ISSN 0014-2956, pages 1628 - 1644, XP009045309
OPPOSITION- H. Wang, "Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19991123), vol. 96, no. 24, doi:10.1073/pnas.96.24.13989, ISSN 00278424, pages 13989 - 13994, XP055005829
OPPOSITION- BEHLKE M A, "Chemical modification of siRNAs for in vivo use", Oligonucleotides, (20081201), vol. 18, no. 4, doi:10.1089/OLI.2008.0164, ISSN 1545-4576, pages 305 - 320, XP002546697
OPPOSITION- YOO et al., "2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro", Nucleic Acids Research, (20040000), vol. 32, no. 6, pages 2008 - 2016, XP055156919
OPPOSITION- KRIITZFELDT J et al., "Specificity, duplex degradation and subcellular localization of antagomirs", Nucleic Acids Res., (20070000), vol. 35, no. 9, doi:10.1093/NAR/GKM024, pages 2885 - 92, XP002532650
OPPOSITION- KRÜTZFELDT et al., "Specificity, duplex degradation and subcellular localization of antagomirs", Nucleic Acids Research, (20070000), vol. 35, no. 9, pages 2885 - 2892, XP002532650
OPPOSITION- Barrangou R; Birmingham A; Wiemann S; Beijersbergen R L; Hornung V; Smith A V B, "Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference", Nucleic Acids Research, (20150000), vol. 43, no. 7, pages 3407 - 3419, XP055203983
OPPOSITION- BARRANGOU R et al., "Advances in CRISPR-Cas9 genome knowledge engineering: lessons learned from RNA interference", Nucleic Acids Res., vol. 43, no. 7, doi:10.1093/nar/gkv226, (20150323), pages 3407 - 19, XP055203983
OPPOSITION- RYAN DE et al., "Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs", Nucleic Acids Res., (20180125), vol. 46, no. 2, doi:10.1093/nar/gkx1199, pages 792 - 803, XP055643341
OPPOSITION- O’reilly Daniel; Kartje Zachary J; Ageely Eman A; Malek-Adamian Elise; Habibian Maryam; Schofield Annabelle; Barkau Christopher L; Rohilla Kushal J; Derossett Lauren B; Weigle Austin T; Damha Masad J; Gagnon Keith T, "Extensive CRISPR RNA modification reveals chemical compatibility and structure- activity relationships for Cas9 biochemical activity", Nucleic Acids Res., (20190125), vol. 47, no. 2, pages 546 - 558, XP055780518
OPPOSITION- Jinek M; Chylinski K; Fonfara I; Hauer M; Doudna J A; Charpentier E, "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity", Science, (20120000), vol. 337, no. 6096, pages 816 - 821, XP055067740
OPPOSITION- JINEK et al., "Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation", Science, (20140000), vol. 343, no. 6176, pages 1247997 - 1247997, XP055149157
OPPOSITION- J. A. Doudna, E. Charpentier, "The new frontier of genome engineering with CRISPR-Cas9", Science, American Association for the Advancement of Science, (20141128), vol. 346, no. 6213, doi:10.1126/science.1258096, ISSN 00368075, page 1258096, XP055162699
OPPOSITION- C. Frank Bennett, Eric E. Swayze, "RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform", Annual Review of Pharmacology and Toxicology, Annual Reviews Inc., (20100201), vol. 50, no. 1, doi:10.1146/annurev.pharmtox.010909.105654, ISSN 03621642, pages 259 - 293, XP055055378
OPPOSITION- COREY D R, "Chemical modification: the key to clinical application of RNA interference ?", THE JOURNAL OF CLINICAL INVESTIGATION, (20071203), vol. 117, no. 12, doi:10.1172/JCI33483, pages 3615 - 3622, XP002558508
OPPOSITION- Megan Basila, Melissa Kelley, Anja Van Brabant Smith, Stefan Maas, "Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity", PLOS ONE, Public Library of Science, (20171127), vol. 12, no. 11, doi:10.1371/journal.pone.0188593, page e0188593, XP055569679
OPPOSITION- Alessandro Laganã; Dennis Shasha; Carlo Maria Croce, "Synthetic RNAs for Gene Common general Regulation: Design Principles and Computational Tools", Frontiers in Bioengineering and Biotechnology, (20141211), vol. 2, page 65, XP055208972
OPPOSITION- Carmen Bertoni, "Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells", Frontiers in Physiology, vol. 5, doi:10.3389/fphys.2014.00148, XP055410411

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents